Skip to main content
. Author manuscript; available in PMC: 2016 Aug 1.
Published in final edited form as: Bone. 2015 Apr 17;77:50–56. doi: 10.1016/j.bone.2015.04.021

Figure 4.

Figure 4

Influence of anti-sclerostin antibody treatment, with and without lowering PTH, on the vertebral phenotype of animals with CKD. (A) cortical thickness, (B) trabecular BV/TV, (C) ultimate load, and (D) energy to failure. Groups with different letters are significantly different (p < 0.05). For all parameters, the overall ANOVA p value was < 0.05. NL – normal littermates; CKD – animals with chronic kidney disease with high PTH levels; CKD-Ca – animals with chronic kidney disease treated with calcium to lower remodeling and PTH; CKD-SCL – animals with chronic kidney disease treated with anti-sclerostin antibody; CKD-SCL-Ca – animals with chronic kidney disease treated with anti-sclerostin antibody and calcium (to lower PTPH).